Clinical trials in Chaidari – page 61

1 008 clinical trials in Chaidari, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GreeceΚλινικεσΔοκιμεσ.gr

Chaidari at a glance

1 008

clinical trials

Research sites1

Quick filters

1 008 trials in Chaidari

Open in trial search

Multiple sclerosis+1

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug

Greece

Participants:18–64 years
Substances:Methylprednisolone
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Multiple sclerosis+2

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Relapsing Multiple Sclerosis

Registered drug

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Relapsing Multiple Sclerosis

Registered drug

Greece

Participants:18–64 years
Substances:Methylprednisolone
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Autoimmune haemolytic anaemia

Not recruiting

Study on Nipocalimab for Adults with Warm Autoimmune Hemolytic Anemia

Registered drug

Study on Nipocalimab for Adults with Warm Autoimmune Hemolytic Anemia

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Nipocalimab
Sponsor:Janssen Cilag International

Contact Research Centre

Non-small cell lung cancer+2

Not recruiting

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study of Elranatamab, Dexamethasone, and Diphenhydramine Hydrochloride for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo

Study of Elranatamab, Dexamethasone, and Diphenhydramine Hydrochloride for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Janssen Cilag International

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study of Isatuximab, Lenalidomide, and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo

Study of Isatuximab, Lenalidomide, and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Severe myoclonic epilepsy of infancy+1

Not recruiting

Study on Long-Term Safety of Soticlestat for Patients with Dravet or Lennox-Gastaut Syndromes

InvestigationalNo placebo

Study on Long-Term Safety of Soticlestat for Patients with Dravet or Lennox-Gastaut Syndromes

InvestigationalNo placebo

Greece

Participants:0–17 years · 18–64 years
Substances:Soticlestat
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study Comparing Entrectinib and Crizotinib for Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Changes, With or Without Brain Metastases

Registered drugNo placebo

Study Comparing Entrectinib and Crizotinib for Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Changes, With or Without Brain Metastases

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Crizotinib
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab and Tretinoin in Patients with PD-1 Refractory Melanoma

Registered drugNo placebo

Study on the Safety and Effectiveness of Pembrolizumab and Tretinoin in Patients with PD-1 Refractory Melanoma

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Lenvatinib
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Follicular lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

Investigational

Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Urinary tract infection

Not recruiting

Title: Comparison of oral tebipenem pivoxil versus intravenous imipenem-cilastatin in adults with complicated urinary tract infection or acute pyelonephritis

Registered drug

Title: Comparison of oral tebipenem pivoxil versus intravenous imipenem-cilastatin in adults with complicated urinary tract infection or acute pyelonephritis

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Cilastatin
Sponsor:Spero Therapeutics Inc.

Contact Research Centre

Other cities in Greece

The busiest research cities in the country

All 45 cities in Greece

Clinical research in Chaidari

What the registry says about research in the country

01 Head and Neck Cancer Research

Innovative clinical research focusing on squamous cell carcinoma of the head and neck, exploring combination therapy approaches that integrate immunotherapy with traditional treatments.

Immunotherapy Integration
Combination Treatment Strategies
Post-Surgery Care

The study evaluates the effectiveness of combining nivolumab with standard cisplatin-radiotherapy, aiming to improve disease-free survival rates in patients with resected head and neck cancer.

Back to Greece All countries